Payment overview · 2025
General Payments
$1,984.05
46 reported records · 10 companies
Healthcare provider profile · identity verified
Matthew Patrick Berryman, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BEND, OR · NPI 1730836719
Verified facts
What the public records show
CMS Open Payments records show Matthew Patrick Berryman, FNP-C received $1,984.05 in general payments during 2025 across 46 reported records.
Surgenex LLC accounted for 39.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Surgenex LLC | Unresolved — no canonical attribution shown | $789.08 | 39.8% | 16 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $402.70 | 20.3% | 15 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $301.43 | 15.2% | 3 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $241.45 | 12.2% | 3 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $89.91 | 4.5% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $60.45 | 3.0% | 2 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $35.19 | 1.8% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $25.06 | 1.3% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $22.57 | 1.1% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $16.21 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,984.05 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $789.08 | 16 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $789.08 | 16 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $789.08 | 16 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $789.08 | 16 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $789.08 | 16 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $166.06 | 7 | 2025 |
Source payment records
|
|||||
| SIMPLIMAX Normalized: simplimax |
Medical Supply | Organogenesis Inc. | $120.33 | 1 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $117.50 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $106.71 | 3 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $89.91 | 2 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $65.62 | 3 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $64.31 | 2 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $63.60 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $60.45 | 2 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $35.19 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| Pounce LP Thrombectomy Normalized: pounce lp thrombectomy |
Device | Surmodics, Inc. | $22.57 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $22.57 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $22.57 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $22.57 | 2 | 2025 |
Source payment records
|
|||||
| Pounce XL Thrombectomy Normalized: pounce xl thrombectomy |
Device | Surmodics, Inc. | $22.57 | 2 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 16 | 13 |
| Eliquis | Apixaban | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Cilostazol | Cilostazol | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,984.05 · 46 records | Surgenex LLC | ArdeoGraft, CYGNUS DUAL, ENROUTE Transcarotid Neuroprotection System, General - Vascular Intervention, JETSTREAM SC, PURAPLY WOUND MATRIX, PelloGraft, Pounce LP Thrombectomy, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Pounce XL Thrombectomy, Ranger, RenoGraft, Restrata Wound Matrix, RotarexS 6 F x 135 cm, SIMPLIMAX, STRAVIX PL, SurGraft, SurMatrix, TREO ABDOMINAL STENT-GRAFT SYSTEM, bio-ConneKt | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error